Skip to main content
AngioLab, Inc. logo

AngioLab, Inc. — Investor Relations & Filings

Ticker · 251280 ISIN · KR7251280004 KO Professional, scientific and technical activities
Open in API
Filings indexed 173 across all filing types
Latest filing 2022-03-22 Annual Report
Country KR South Korea
Listing KO 251280

About AngioLab, Inc.

https://angiolab.co.kr/

AngioLab, Inc. is a biotechnology company specializing in the discovery and development of angiogenesis inhibitors. The company develops pharmaceuticals and health functional foods to treat diseases associated with the abnormal growth of blood vessels. Its pipeline includes drug candidates targeting conditions such as age-related macular degeneration (AMD), with some candidates having undergone Phase II clinical trials. AngioLab has also developed Ob-X, a functional food ingredient based on its anti-angiogenic research platform.

Recent filings

Filing Released Lang Actions
사업보고서 (2021.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the fiscal year 2021 (2021.01.01-2021.12.31) submitted to the Financial Supervisory Service and Korea Exchange. In the Korean regulatory context, the 'Business Report' (사업보고서) is the equivalent of the US 10-K, serving as the comprehensive annual report containing financial statements, business overview, and governance information. It is not an announcement or a summary, but the full statutory filing. FY 2021
2022-03-22 Korean
임상시험단계진입ㆍ종료(자율공시)(비알코올성 지방간염(NASH) 치료제 AL101-NASH의 임상2a상 종료)
Legal Proceedings Report Classification · 1% confidence The document is a formal regulatory disclosure from a Korean company (AngioLab) regarding the completion of a Phase 2a clinical trial for a drug candidate (AL101-NASH). It details the trial methodology, results, safety data, and future plans. In the context of financial filings, clinical trial results are categorized as regulatory announcements or filings that do not fit into standard financial reporting categories like 10-K or Earnings Releases. Given the specific nature of the disclosure, it falls under the 'Regulatory Filings' (RNS) category as a fallback for miscellaneous corporate announcements.
2022-03-17 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for AngioLab, dated March 14, 2022. It contains the meeting agenda, details on voting procedures, and management information (such as director activities and remuneration). This document is a standard proxy statement/notice sent to shareholders to inform them of the upcoming AGM and solicit their votes, which fits the definition of a Proxy Solicitation & Information Statement.
2022-03-14 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집 결의) issued by AngioLab. It details the date, location, and agenda items for the upcoming meeting, including the approval of financial statements, election of directors, and remuneration limits. This type of document is sent to shareholders to provide information and request votes for the meeting, which aligns with the definition of a Proxy Solicitation & Information Statement.
2022-03-10 Korean
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a short regulatory filing (773 characters) submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company is holding its AGM on a date that coincides with many other companies, citing audit schedules and reporting timelines. It does not contain the actual AGM materials or voting results, but rather serves as a formal regulatory notification. As it is a specific regulatory disclosure that does not fit into the other categories like AGM-R or DVA, it is classified as a Regulatory Filing (RNS).
2022-03-10 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a '정정신고' (Correction Report). It details changes to previously granted stock options, including adjustments to the number of shares and the list of recipients. In the context of financial filings, reports regarding the issuance or modification of stock options (equity-based compensation) are classified as regulatory filings related to capital structure or share-based incentives. Since it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes), it falls under the 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement.
2022-02-11 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.